Back to search results

Combination Chemotherapy and Nelarabine for T-cell Leukemia or Lymphoma

This study is looking at how well a combination of chemotherapy drugs, including cyclophosphamide, cytarabine, dexamethasone, doxorubicin, mercaptopurine, and nelarabine, works for people with T-cell acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma. It also studies the side effects of these treatments. The goal is to see how many people achieve complete remission (cancer goes away), how long that remission lasts, and how long people live without their cancer getting worse. You may be able to join if you have previously untreated T-cell ALL or lymphoblastic lymphoma, or if your cancer didn't respond to one round of chemotherapy. The study is currently unclear about its recruitment status and plans to enroll 160 participants.

Study design
This is an interventional study, meaning participants will receive specific treatments. It is a Phase II trial, which typically focuses on how well a new treatment works and its safety, and plans to enroll 160 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track your complete remission rate and progression-free survival for at least 3 years, and your duration of remission for up to 9 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00501826

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recruiting
PHASE2All AgesInterventionalTreatment
M.D. Anderson Cancer Center
~160 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:CyclophosphamideCytarabineDexamethasoneDoxorubicin HydrochlorideMercaptopurineMethotrexate

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Complete remission rate
Measured over 3 years
+3 more outcomes measured

Conditions

T Acute Lymphoblastic Leukemia
T Lymphoblastic Lymphoma

Explore related trials

Pre T-ALLT Lymphoblastic Lymphoma

NCT00501826

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • M D Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Farhad Ravandi-Kashani · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Farhad Ravandi-Kashani, MD
713-745-0394
Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Previously untreated T cell ALL including T cell lymphoblastic lymphoma; failure to one induction course of chemotherapy are eligible; patients in CR after =\< 2 courses are also eligible
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3
Serum bilirubin less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 5.0 mg/dL is acceptable
Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) less than or equal to 4 x upper limit of normal (ULN)
Serum creatinine less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 2.5 mg/dL is acceptable

Exclusion

Pregnant or nursing women

What this trial measures

  • Complete remission rate3 years

    The sample size will provide an estimate of relapse rate at 3 years with a 95% confidence interval of width +/- 10%.

  • Duration of remissionUp to 9 years

    Duration of remission will be evaluated.

  • Progression-free survival3 years

    Progression-free survival will be estimated.

  • Overall survival3 years

    Overall survival will be estimated.